Proton pump inhibitor use and cardiovascular risk, all-cause, and cardiovascular mortality across baseline eGFR categories: a longitudinal study.

ABSTRACT: This longitudinal cohort study aimed to evaluate the associations of proton pump inhibitor (PPI) use and estimated glomerular filtration rate (eGFR) with cardiovascular disease (CVD) risk, all-cause mortality, and cardiovascular mortality. We analysed data from 30,362 National Health and Nutrition Examination Survey participants (mean age: 49.3 ± 17.6 years; 51.1% women) between 2003 and 2018. Participants were categorised into eight subgroups based on PPI use and eGFR categories. CVD risk was assessed using survey-weighted multivariable logistic regression, while mortality was evaluated with Cox proportional hazards models over a median follow-up of 91 months. Analyses were adjusted for numerous potential confounders, with sensitivity analyses validating the results. Compared to nonusers

SUBMITTER: Zhang T 

PROVIDER: S-EPMC12720677 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature